AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 129 filers reported holding AIMMUNE THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.94 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $2,433,000 | -3.5% | 108,875 | +3.3% | 0.00% | -25.0% |
| Q4 2018 | $2,521,000 | -55.2% | 105,410 | -48.9% | 0.00% | +33.3% |
| Q3 2018 | $5,624,000 | +154.0% | 206,156 | +150.4% | 0.00% | 0.0% |
| Q2 2018 | $2,214,000 | +9.3% | 82,327 | +29.4% | 0.00% | 0.0% |
| Q1 2018 | $2,025,000 | -15.8% | 63,620 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $2,406,000 | +50.5% | 63,620 | -1.4% | 0.00% | +50.0% |
| Q3 2017 | $1,599,000 | +23.4% | 64,495 | +2.3% | 0.00% | 0.0% |
| Q2 2017 | $1,296,000 | +34.4% | 63,037 | +42.1% | 0.00% | +100.0% |
| Q1 2017 | $964,000 | +9.0% | 44,349 | +2.6% | 0.00% | 0.0% |
| Q4 2016 | $884,000 | +39.7% | 43,229 | +2.4% | 0.00% | 0.0% |
| Q3 2016 | $633,000 | +38.5% | 42,204 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $457,000 | +101.3% | 42,204 | +151.6% | 0.00% | – |
| Q1 2016 | $227,000 | -26.5% | 16,771 | 0.0% | 0.00% | -100.0% |
| Q4 2015 | $309,000 | +8.0% | 16,771 | +48.5% | 0.00% | 0.0% |
| Q3 2015 | $286,000 | – | 11,294 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TLP GROUP LLC | 2,904,185 | $43,563,000 | 46.00% |
| Foresite Capital Management II, LLC | 3,967,900 | $59,519,000 | 28.42% |
| Aisling Capital LLC | 2,990,000 | $44,850,000 | 9.24% |
| Foresite Capital Management III, LLC | 935,020 | $14,025,000 | 6.56% |
| Vivo Capital, LLC | 763,009 | $11,445,000 | 3.57% |
| RA Capital Management | 1,292,940 | $19,394,000 | 2.00% |
| Palo Alto Investors LP | 379,727 | $5,696,000 | 0.33% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 418,214 | $6,273,000 | 0.32% |
| EMERALD ADVISERS, LLC | 464,364 | $6,965,000 | 0.31% |
| Rock Springs Capital Management LP | 293,000 | $4,395,000 | 0.28% |